NG
NG2.F Neogen Corporation
- Market cap
- EUR 2.25B
- P/E
- -
- P/B
- 1.21x
- ROE
- -2.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Aug 2026.
Is NG2.F undervalued?
Graham numberThe Graham number of Neogen Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Neogen Corporation fundamental analysis
No fundamental analysis for Neogen Corporation yet.
Neogen Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Neogen Corporation
Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments. The company offers diagnostic test kits and complementary products to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation…
Full company profileNeogen Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Aug 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Neogen Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 362M | 402M | 414M | 418M | 468M | 527M | 822M | 924M | 895M | 870M | 891M |
| Gross Profit | 172M | 190M | 192M | 196M | 215M | 243M | 406M | 464M | 421M | 409M | 422M |
| Operating Income | 64.9M | 70.2M | 68.1M | 67.5M | 74.2M | 58.6M | 37.5M | 58.6M | -1.70M | -21.6M | -7.20M |
| EBITDA | 79.6M | 87.3M | 85.7M | 85.9M | - | 82.3M | 124M | 174M | -939M | 171M | 117M |
| Net Income | 43.8M | 63.1M | 60.2M | 59.5M | 60.9M | 48.3M | -22.9M | -9.40M | -1.09B | -7.90M | -47.6M |
| EPS | 0.86 | 0.61 | 0.58 | 0.56 | 0.57 | 0.45 | -0.11 | -0.04 | -5.03 | -0.04 | -0.22 |
| Balance Sheet | |||||||||||
| Total Assets | 528M | 618M | 696M | 797M | 920M | 993M | 4.55B | 4.55B | 3.44B | 3.35B | 3.30B |
| Total Liabilities | 56.7M | 57.8M | 57.8M | 72.0M | 79.8M | 106M | 1.42B | 1.40B | 1.37B | 1.25B | 1.22B |
| Shareholders' Equity | 472M | 560M | 638M | 725M | 840M | 887M | 3.13B | 3.14B | 2.07B | 2.09B | 2.09B |
| Cash & Short-term Investments | 77.6M | 83.1M | 41.7M | 66.3M | 381M | 44.5M | 163M | 171M | 129M | 186M | 172M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 60.3M | 69.1M | 63.8M | 85.9M | 81.1M | 68.0M | 41.0M | 35.3M | 58.2M | 83.2M | 51.6M |
| Capital Expenditure | 14.6M | 20.9M | 24.1M | 24.1M | 26.7M | 24.4M | 65.8M | 111M | 105M | 51.3M | 32.8M |
| Free Cash Flow | 45.7M | 48.2M | 49.2M | 61.8M | 54.4M | 43.6M | -24.7M | -76.1M | -46.4M | 31.9M | 18.8M |
| Ratios | |||||||||||
| ROE | 9.3% | 11.3% | 9.4% | 8.2% | 7.2% | 5.4% | -0.7% | -0.3% | -52.7% | -0.4% | -2.3% |
| ROA | 8.3% | 10.2% | 8.6% | 7.5% | 6.6% | 4.9% | -0.5% | -0.2% | -31.7% | -0.2% | -1.4% |
| Net Profit Margin | 12.1% | 15.7% | 14.5% | 14.2% | 13.0% | 9.2% | -2.8% | -1.0% | -122.1% | -0.9% | -5.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Neogen Corporation dividends
Neogen Corporation has not paid dividends in the last 9 fiscal years.
Last stock split: 2:1 on Jun 7, 2021.
Who owns Neogen Corporation
- Insiders 0.79%
- Institutions 99.21%
- Public & others 0.00%
- Shares outstanding 218M
- Free float 217M
Neogen Corporation company profile
- Company name
- Neogen Corporation
- Ticker
- NG2.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2,636
- Fiscal year end
- May
- Address
- 620 Lesher Place, Lansing, MI, United States, 48912-1595
- Phone
- 517 372 9200
- Website
- neogen.com
About Neogen Corporation
Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments. The company offers diagnostic test kits and complementary products to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns. It also provides reagents and test kits used in immunoassay production, forensic and animal toxicology, and life science research; unique colorimetric and chemiluminescent substrates for research use; veterinary instruments and delivery systems under the Ideal and Prima Tech brands; and precision instruments designed for injections, topical and oral administration, artificial insemination, and animal identification for farmers, ranchers, and veterinarian under the Prima Tech brand. In addition, the company offers digestive aids and nutritional supplements; Natural Vitamin E-AD to address vitamin deficiencies in swine, cattle, and sheep; RenaKare; companion animal parasiticides under Provecta brand; BotVax B; EqStim; ImmunoRegulin; companion animal parasiticides under the Provecta brand; rodent and insect control products under the Ramik, CyKill, Havoc, Prozap, SureKill, and StandGuard brands. Further, it markets Uniprim, a veterinary antibiotic; operates sgenomics labs offering DNA genotyping, sequencing, and trait analysis for livestock and companion animals; and provides software systems that help testers to analyze and store results and perform analysis. The company has a strategic collaboration with Hinalea Imaging Corp. to develop digital imaging solutions for food safety and quality inspection. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.
Neogen Corporation management
10- Mr. Mikhael NassifCEO, President & Director · born 1976
- Mr. R. Bryan Riggsbee CPACFO & Senior Vice President · born 1970
- Ms. Jennifer Evans Stacey Esq., J.D.Senior VP, Chief Legal & Compliance Officer and Board Secretary · born 1965
- Dr. Tamara A. Ranalli Ph.D.Senior VP & GM of Global Food Safety · born 1973
- Mr. John MoylanVP, Corporate Controller & Chief Accounting Officer
- Dr. Jeremy YarwoodChief Scientific Officer
- Sarah DemeyAdministrative Manager
- Mr. Kevin M. BurkeChief Human Resources Officer · born 1969
- Mr. Joe FreelsSenior VP & Chief Commercial Officer
- Mr. Jim WalterSenior Vice President of Manufacturing & Operations